Philip He
Impact in
- Hepatology top 5%
- Hepatocellular Carcinoma Treatment and Prognosis
- Oncology top 10%
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
Papers in
- Oncology 15
- Cancer Immunotherapy and Biomarkers 10
- Colorectal Cancer Treatments and Studies 6
-
- Lung Cancer Treatments and Mutations 6
- Co-authors
- Alejandra Negro (6 shared papers)Robin Kate Kelley (5 shared papers)Ghassan K. Abou‐Alfa (5 shared papers)Yoon‐Koo Kang (2 shared papers)Bruno Sangro (2 shared papers)Masatoshi Kudo (2 shared papers)Lorenza Rimassa (1 shared paper)Vincent C. Tam (1 shared paper)
- Journals
- Journal of Clinical Oncology (7 papers)Journal of Thoracic Oncology (2 papers)Pharmaceutical Statistics (2 papers)Therapeutic Innovation & Regulatory Science (2 papers)Clinical Cancer Research (1 paper)
- Partner nations
- United StatesJapanSpain
In The Last Decade
Philip He
19 papers receiving 456 citations
Philip He's Hit Papers
Peers
Comparison fields: 5 of 38
- Hepatology 270
- Oncology 279
- Pathology and Forensic Medicine 92
- Immunology 84
- Pulmonary and Respiratory Medicine 106
Countries citing papers authored by Philip He
This map shows the geographic impact of Philip He's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip He with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip He more than expected).
Fields of papers citing papers by Philip He
This network shows the impact of papers produced by Philip He. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip He. The network helps show where Philip He may publish in the future.
Co-authors
The 25 scholars most cited alongside Philip He, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 22 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. Hit paper breakdown → | 2022 | 259 |
| 2 | 2020 | 82 | |
| 3 | 2020 | 24 | |
| 4 | 2022 | 21 | |
| 5 | 2021 | 19 | |
| 6 | 2022 | 14 | |
| 7 | 2019 | 7 | |
| 8 | 2021 | 6 | |
| 9 | 2021 | 5 | |
| 10 | 2019 | 5 | |
| 11 | 2019 | 4 | |
| 12 | 2020 | 3 | |
| 13 | 2024 | 2 | |
| 14 | 2024 | 2 | |
| 15 | 2021 | 2 | |
| 16 | 2024 | 1 | |
| 17 | Timing of onset and resolution of adverse events in patients with unresectable stage IIIB-IVM1a melanoma treated with talimogene laherparepvec (T-VEC) in OPTiM | 2016 | 1 |
| 18 | 2024 | 1 | |
| 19 | 2017 | 1 | |
| 20 | 2025 | 0 |
About Philip He
Philip He is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Surgery, Statistics and Probability and Cancer Research, having authored 22 papers that have together received 459 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (10 papers), Colorectal Cancer Treatments and Studies (6 papers), Lung Cancer Treatments and Mutations (6 papers), Statistical Methods in Clinical Trials (5 papers), Cancer Genomics and Diagnostics (5 papers), Hepatocellular Carcinoma Treatment and Prognosis (3 papers), Bladder and Urothelial Cancer Treatments (3 papers) and Lymphoma Diagnosis and Treatment (2 papers). The work is most often cited by research in Hepatology (270 citations), Oncology (279 citations), Pathology and Forensic Medicine (92 citations), Immunology (84 citations) and Pulmonary and Respiratory Medicine (106 citations). Philip He has collaborated with scholars based in United States, Japan and Spain. Frequent co-authors include Alejandra Negro, Robin Kate Kelley, Ghassan K. Abou‐Alfa, Yoon‐Koo Kang, Bruno Sangro, Masatoshi Kudo, Lorenza Rimassa, Vincent C. Tam, Wattana Sukeepaisarnjaroen and Tu Van Dao. Their work appears in journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology, Pharmaceutical Statistics, Therapeutic Innovation & Regulatory Science and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.